Plaque psoriasis
Conditions
Interventions
Sponsors
Nemoto Takanori
Torii Pharmaceutical Co.,LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese patients aged >= 18 years at informed consent who can visit the study site as an outpatient 2. Patients with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months at informed consent 3. Patients whose PGA score, PASI score, and %BSA affected meet the criteria specified in the study protocol
Exclusion criteria
Exclusion criteria: 1. Patients with psoriasis other than plaque variant 2. Patients with a history of or current significant dermatologic or inflammatory condition that, in the investigator's opinion, would make it difficult to interpret data or assessments during the study 3. Patients with a history of or current acute active bacterial, fungal, or viral (e.g., herpes simplex, herpes zoster, and varicella) skin infection within 1 week prior to Week 0 4. Patients who have used any prohibited therapy specified in the study protocol within the indicated period before Week 0 5. Patients with serious concomitant disease(s) 6. Patients with a history of or current cancer within 5 years prior to screening visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events and adverse drug reactions Change from Baseline and clinically significant abnormalities in laboratory test results Change from Baseline and clinically significant abnormalities in vital signs | — |
Contacts
Public Contactclinical trials information
Shionogi & Co.,Ltd.
Outcome results
None listed